Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...

Through this equation, you can identify the vertex, axis of symmetry and the direction in which the parabola opens. Follow these steps to draw a parabola with the given equation: y = 2 2 − 4x ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...

"And it could be so much more," he said. To that end, Florida Tech has relaunched the underutilized Center for Advanced Manufacturing and Innovative Design as Vertex, a new "applied innovation hub." ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...